Literature DB >> 33681091

Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma.

Hideo Suzuki1, Motoyuki Kohjima1,2, Masatake Tanaka1,3, Takeshi Goya1, Shinji Itoh4, Tomoharu Yoshizumi4, Masaki Mori4, Mariko Tsuda1, Motoi Takahashi1, Miho Kurokawa1, Koji Imoto1, Shigeki Tashiro1, Akifumi Kuwano1, Masaki Kato1,5, Seiji Okada3, Makoto Nakamuta2, Yoshihiro Ogawa1,6.   

Abstract

Objective: Metabolic alteration is widely considered as one of the hallmarks of cancer. Hepatocellular carcinoma (HCC) presents a unique pathological feature in which lipid accumulation is common in well-differentiated HCC and rare in poorly differentiated HCC; however, the underlying mechanism remains unclear.
Methods: Tissue samples were obtained from 103 HCC patients who had undergone hepatic resection and 12 living donors of liver transplantation. We evaluated metabolic gene expressions in cancer tissues as well as background noncancer tissues and compared the expressions by the degree of cancer differentiation and by liver disease states. Besides, the metabolomics was evaluated and integrated to gene expressions in nonalcoholic steatohepatitis (NASH)-HCC model mice.
Results: In cancer tissues, the expression levels of enzymes related to glycolysis, pentose phosphate pathway (PPP), and fatty acid (FA) synthesis were increased and that of tricarboxylic acid (TCA) cycle and β-oxidation were suppressed. Same metabolic alterations were observed in noncancer tissue as the liver disease progresses from healthy liver to chronic hepatitis, cirrhosis, and HCC. Similar alterations of metabolic genes were detected in NASH-HCC mice, which were consistent with the results of metabolomics. As the degree of cancer differentiation decreased, glycolysis and PPP were accelerated; however, FA synthesis and uptake were diminished. Conclusions: The metabolic alterations including glycolysis, PPP, TCA cycle, and β-oxidation became more prominent as liver disease progresses from normal, chronic hepatitis, cirrhosis, well-, moderately, and poorly differentiated HCC. FA synthesis and uptake were highest in well-differentiated HCC, which could explain the lipid accumulation.
Copyright © 2021 Hideo Suzuki et al.

Entities:  

Year:  2021        PMID: 33681091      PMCID: PMC7910064          DOI: 10.1155/2021/8813410

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  39 in total

Review 1.  Pyruvate kinase type M2 and its role in tumor growth and spreading.

Authors:  Sybille Mazurek; C Bruce Boschek; Ferdinand Hugo; Erich Eigenbrodt
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

Review 2.  Crucial role of the pentose phosphate pathway in malignant tumors.

Authors:  Lin Jin; Yanhong Zhou
Journal:  Oncol Lett       Date:  2019-03-05       Impact factor: 2.967

Review 3.  Potential for statins in the chemoprevention and management of hepatocellular carcinoma.

Authors:  Amedeo Lonardo; Paola Loria
Journal:  J Gastroenterol Hepatol       Date:  2012-11       Impact factor: 4.029

Review 4.  The pentose phosphate pathway and cancer.

Authors:  Krushna C Patra; Nissim Hay
Journal:  Trends Biochem Sci       Date:  2014-07-15       Impact factor: 13.807

5.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

6.  EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.

Authors:  Weiwei Yang; Yan Xia; Yu Cao; Yanhua Zheng; Wen Bu; Lin Zhang; M James You; Mei Yee Koh; Gilbert Cote; Kenneth Aldape; Yi Li; Inder M Verma; Paul J Chiao; Zhimin Lu
Journal:  Mol Cell       Date:  2012-11-01       Impact factor: 17.970

7.  Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human.

Authors:  J Rowles; S W Scherer; T Xi; M Majer; D C Nickle; J M Rommens; K M Popov; R A Harris; N L Riebow; J Xia; L C Tsui; C Bogardus; M Prochazka
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

8.  PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.

Authors:  Jiao Feng; Liwei Wu; Jie Ji; Kan Chen; Qiang Yu; Jie Zhang; Jiaojiao Chen; Yuqing Mao; Fan Wang; Weiqi Dai; Ling Xu; Jianye Wu; Chuanyong Guo
Journal:  J Exp Clin Cancer Res       Date:  2019-05-17

9.  High Expression of Glycolytic Genes in Cirrhosis Correlates With the Risk of Developing Liver Cancer.

Authors:  Nathan C W Lee; Maria Annunziata Carella; Salvatore Papa; Concetta Bubici
Journal:  Front Cell Dev Biol       Date:  2018-10-31

Review 10.  Lipid metabolic reprogramming in cancer cells.

Authors:  S Beloribi-Djefaflia; S Vasseur; F Guillaumond
Journal:  Oncogenesis       Date:  2016-01-25       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.